Biotech Values

[biomaven0]

Here's a paper that describes the Ph II data - the linear model with repeated measurements assumes that the rate of decline is linear, with the expectation that the slopes of the drug and placebo would be different. I guess it is an attempt to display disease modification rather than just a temporary one-time improvement. In actual practice the linear model didn't fit the actual data very well.

http://www.butler.org/documents/2009_Salloway_Phase_2.pdf

It is disconcerting how much of the effect was from a placebo group that did unexpectedly badly.

Peter